Cure My Disease

Don't miss your cure!

 Log in / Sign up

Electronic nudge aims to close the gap in heart failure treatment

NCT ID NCT05433220

Disease control Sponsor: Inova Health Care Services Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study tests whether an electronic alert in a patient's medical record can prompt doctors to prescribe guideline-recommended heart failure medications that are not yet being used. The trial includes 5,000 adults with heart failure and a reduced ejection fraction (≤40%) seen at Inova clinics or hospitals. Half of the doctors will receive the alert when they open a patient's chart; the other half will continue with usual care. The goal is to see if the alert increases the number of patients on appropriate medications within 30 days.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Best practice advisory alert via electronic health record
What this could lead to
If effective, this alert system could help more heart failure patients receive life-saving medications, potentially reducing hospitalizations and deaths.
What could go wrong
The alert may not change prescribing habits, or doctors might ignore it. The study only measures short-term outcomes (30 days), so long-term benefits are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 5,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2022

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age\>18 Years * Seen by a Cardiologist in an Inova clinic or Inova hospital setting * Left Ventricular Ejection Fraction ≤40% Exclusion Criteria: * Opted out of EHR-based research * Hospice care * Already receiving maximally titrated doses of each of the four classes of evidence- based HFrEF medical therapy * Prior heart transplant

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Inova Health System

    RECRUITING

    Falls Church, Virginia, 22042, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.